SS-31 (Elamipretide)

Mechanism of Action

SS-31 (Elamipretide) is a mitochondria-targeted therapeutic peptide that works primarily by preserving and restoring mitochondrial function through several interconnected molecular mechanisms.

Mitochondrial Membrane Targeting and Cardiolipin Interaction

The compound selectively targets mitochondria and appears to interact with cardiolipin, a key phospholipid in the inner mitochondrial membrane. Evidence suggests SS-31 modulates membrane binding properties, which is crucial for maintaining proper mitochondrial membrane structure and function.

Bioenergetic Preservation

Recent research demonstrates that SS-31 preserves mitochondrial bioenergetics across multiple organ systems. In skeletal muscle models of heart failure with preserved ejection fraction (HFpEF), the compound improved muscle performance by targeting underlying mitochondrial dysfunction. Similarly, in spinal cord injury models, SS-31 promoted recovery specifically through preservation of mitochondrial bioenergetic function.

Protein Aggregation Modulation

The peptide shows the ability to modulate pathological protein interactions. Studies indicate SS-31 can influence the membrane binding and aggregation of α-synuclein while simultaneously restoring impaired mitochondrial function, suggesting a dual mechanism that addresses both protein misfolding and cellular energetics.

Anti-oxidant and Anti-inflammatory Effects

SS-31 demonstrates antioxidant properties that appear to work in conjunction with other compounds like N-acetylcysteine to reduce oxidative stress. The compound also shows protective effects against neuroinflammation, potentially through preservation of endothelial glycocalyx integrity and reduction of inflammatory cascades.

Tissue-Specific Neuroprotection

In neural tissues, SS-31 promotes neural remodeling processes while maintaining cellular energy production, contributing to functional recovery after injury.

The evidence base consists primarily of preclinical studies, with limited clinical trial data available. While these mechanisms appear promising across multiple disease models, further clinical validation is needed to fully establish therapeutic efficacy in humans.

This information is for educational purposes only and should not be considered personalized medical advice. Consult healthcare providers for treatment decisions.

Elamipretide (SS-31) is a mitochondria-targeted peptide being investigated for multiple conditions involving mitochondrial dysfunction. The compound has shown potential across several therapeutic areas, though clinical evidence remains limited to early-phase studies.

Primary Clinical Targets

Friedreich's Ataxia
The most advanced clinical application is in Friedreich's ataxia, a rare genetic disorder affecting mitochondrial function. A completed Phase 1/2 investigator-initiated study (NCT05168774) has been conducted, though results are not yet publicly available from the provided evidence.

Preclinical Applications Under Investigation

Recent research has explored elamipretide's potential in several conditions:

Neurological Conditions

• Stroke/Brain Injury: Studies suggest elamipretide may mitigate post-ischemic brain injury, potentially through modulation of inflammatory pathways when combined with other therapies
• Spinal Cord Injury: Research indicates the compound may promote recovery by preserving mitochondrial function and supporting neural remodeling
• Neurodegenerative Disease: Investigations show elamipretide may modulate α-synuclein aggregation and restore mitochondrial function, relevant to conditions like Parkinson's disease
• Age-related Cognitive Impairment: Studies suggest protective effects against neuroinflammation and cognitive decline in aging

Cardiovascular Applications

• Heart Failure with Preserved Ejection Fraction (HFpEF): Research demonstrates improved skeletal muscle performance in animal models through targeting mitochondrial dysfunction

Other Conditions

• Respiratory Disease: Studies explore anti-oxidant mechanisms for ozone-induced airway hyperresponsiveness
• Hepatic Injury: Research investigates protective effects in ischemia-reperfusion injury
• Athletic Performance: Safety and efficacy reviews examine potential applications for musculoskeletal injuries

Clinical Development Status

Evidence for elamipretide's clinical applications remains largely preclinical, with most findings from animal studies published in 2025-2026. While the completed Friedreich's ataxia trial represents the most advanced clinical evaluation, broader clinical validation across these various applications is still needed.

Disclaimer: This information is for educational purposes only and should not be considered personalized medical advice. Consult healthcare professionals for medical guidance.

Safety Profile of Elamipretide (SS-31)

Evidence Limitations: The safety data for elamipretide is currently limited, with most available evidence coming from preclinical animal studies and one completed Phase 1/2 trial. Comprehensive human safety data remains thin, and this assessment should be considered preliminary.

Known Side Effects

Based on the available evidence, specific side effect profiles from human studies are not well-documented in the provided research. The completed Phase 1/2 trial in Friedreich's ataxia patients (NCT05168774) would contain relevant safety data, but detailed results are not included in the evidence provided.

Contraindications

No specific contraindications have been established based on the available evidence. This represents a significant gap in the current safety profile.

Drug Interactions

The evidence does not provide information about drug-drug interactions with elamipretide. One study examined combination therapy with nicotinamide mononucleotide (NMN), suggesting potential for combination approaches, but formal interaction studies are not documented in the available literature.

Special Populations

Evidence is particularly thin regarding safety in special populations, including:

• Pregnant or breastfeeding women
• Pediatric patients
• Elderly patients
• Patients with severe hepatic or renal impairment
• Patients with cardiovascular disease

Preclinical Safety Observations

Animal studies suggest elamipretide may be generally well-tolerated, as evidenced by its use across multiple organ systems (brain, heart, liver, spinal cord) in research models. However, these preclinical findings cannot be directly extrapolated to human safety.

Clinical Considerations

Given the limited human safety data, elamipretide should only be used under appropriate clinical supervision and regulatory oversight. Healthcare providers should exercise particular caution when considering its use, especially in vulnerable populations.

Disclaimer: This safety information is based on limited available evidence and should not replace consultation with healthcare professionals. Patients should not use this compound outside of approved clinical trials or medical supervision.

Key Gap: Comprehensive Phase 3 safety data and post-market surveillance information are not available, representing a significant limitation in establishing a complete safety profile for elamipretide.

Key Research Papers and Clinical Trials

Research on elamipretide (SS-31) has expanded across multiple therapeutic areas, with studies examining its effects on mitochondrial dysfunction in various disease models.

Neurological Applications

Several preclinical studies have investigated elamipretide's neuroprotective properties. A mouse study examined combination therapy with elamipretide and nicotinamide mononucleotide for post-ischemic brain injury, targeting TREM2 pathways. Another study evaluated elamipretide's effects on spinal cord injury recovery, focusing on mitochondrial bioenergetics preservation and neural remodeling. Research has also explored elamipretide's potential in neurodegenerative disease, with one study examining its ability to modulate α-synuclein membrane binding and aggregation while restoring mitochondrial function.

In aged rats, researchers investigated elamipretide's protective role against endothelial glycocalyx degradation, neuroinflammation, and cognitive impairment.

Cardiovascular Research

A rat model study examined elamipretide's effects on skeletal muscle performance in heart failure with preserved ejection fraction (HFpEF), targeting mitochondrial dysfunction as a therapeutic mechanism.

Other Applications

Research has extended to respiratory conditions, with one study investigating elamipretide's mechanisms alongside N-acetylcysteine for ozone-induced airway hyperresponsiveness and mucus hypersecretion. Additionally, studies have explored mitochondria-targeted approaches for hepatic ischemia-reperfusion injury, though specific sample sizes were not provided in the available evidence.

Clinical Development

One completed Phase 1/2 clinical trial (NCT05168774) investigated elamipretide in Friedreich's ataxia patients, though detailed results and participant numbers are not available in the provided evidence.

Note: Sample sizes and specific study designs were not detailed in the available evidence for most studies. This synthesis reflects research published primarily in 2025-2026, indicating ongoing active investigation of elamipretide across multiple therapeutic areas.

Protocols

Based on available literature, elamipretide (SS-31) dosing protocols vary significantly depending on the clinical indication and study design. The evidence for standardized human dosing protocols remains limited, with most published research focusing on preclinical animal models.

Clinical Trial Dosing

Limited clinical trial data is available, with one completed Phase 1/2 study in Friedreich's ataxia (NCT05168774). However, specific dosing protocols from this trial are not detailed in the available evidence.

Preclinical Research Protocols

Animal studies have employed various dosing regimens:

• Route of administration: Studies have used both intravenous and subcutaneous injection routes
• Timing: Protocols have included both acute treatment (single or short-term dosing) and chronic administration
• Disease models: Dosing has been investigated across multiple conditions including ischemic brain injury, heart failure with preserved ejection fraction, spinal cord injury, and hepatic ischemia-reperfusion injury

Administration Considerations

Research indicates elamipretide targets mitochondrial dysfunction through cardiolipin binding and preservation of mitochondrial bioenergetics. Studies suggest the compound may be administered in combination with other therapies, such as nicotinamide mononucleotide (NMN).

Evidence Limitations

The current literature provides insufficient detail regarding standardized human dosing protocols, optimal treatment duration, or established therapeutic windows. Most dosing information derives from preclinical studies, which may not translate directly to human applications.

---

Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Any clinical use of elamipretide should only be undertaken under the supervision of qualified healthcare professionals following appropriate regulatory approval and established clinical protocols.

Outcomes

The reported outcomes for SS-31 (Elamipretide) span multiple therapeutic areas, though the evidence base is limited and primarily derived from preclinical studies with one small clinical trial.

Neurological Outcomes

In preclinical stroke models, SS-31 combination therapy demonstrated measurable neuroprotective effects, including targeting TREM2 pathways to reduce post-ischemic brain injury. For spinal cord injury, the compound showed preservation of mitochondrial bioenergetics and promotion of neural remodeling, though specific functional outcome measures were not detailed in the available abstracts.

In Parkinson's disease models, SS-31 modulated α-synuclein membrane binding and aggregation while restoring impaired mitochondrial function. For age-related cognitive decline, the compound provided protection against endothelial glycocalyx degradation and associated neuroinflammation in aged rats.

Cardiovascular and Muscle Performance

In heart failure with preserved ejection fraction (HFpEF) rat models, SS-31 improved skeletal muscle performance through targeting mitochondrial dysfunction. However, specific performance metrics and the magnitude of improvement were not quantified in the available evidence.

Respiratory Outcomes

For ozone-induced respiratory symptoms, SS-31 demonstrated protective mechanisms against airway hyperresponsiveness and mucus hypersecretion, though measurable clinical endpoints were not specified.

Clinical Trial Evidence

One completed Phase 1/2 clinical trial (NCT05168774) investigated SS-31 in Friedreich's ataxia, but outcome data from this study are not yet available in the provided literature.

Evidence Limitations

The strength of evidence is notably limited. Most reported outcomes derive from animal studies with publication dates in 2025-2026, suggesting very recent or potentially preliminary research. Quantitative outcome measures, effect sizes, and statistical significance data are largely absent from the available abstracts. The single completed clinical trial lacks published results, leaving human efficacy data unavailable.

This information is for research purposes only and does not constitute medical advice. Consult healthcare professionals for treatment decisions.